Table 1 Characteristics of HC and RA patients at baseline and after 3 months of MTX treatment
Control group (HC), n = 15 | Early RA (RA), n = 15 | p (HC vs RA) | MTX at 3 months (RA MTX T1), n = 14 | p (MTX 3 months vs RA) | |
|---|---|---|---|---|---|
Age | 53.3 ± 7.03 | 60 ± 8.06 | 0.25 | ||
Sex (n, %F) | 11 (73.3%) | 11 (73.3%) | 1.0 | ||
Smoking habit | 0.038 | ||||
Never smoker | 11 (73.3%) | 4 (26.7%) | |||
Current smoker | 2 (13.3%) | 6 (40.0%) | |||
Former smoker | 2 (13.3%) | 5 (33.3%) | |||
RF (n, %) | 10 (66.7%) | ||||
ACPA (n, %) | 11 (73.3%) | ||||
TJC | 4.2 ± 7.0 | 3.1 ± 2.3 | 0.041 | ||
SJC | 3.1 ± 1.8 | 0.9 ± 1.1 | 0.331 | ||
CRP (mg/dl) | 1.89 ± 1.36 | 0.92 ± 0.68 | 0.234 | ||
ESR | 26.6 ± 13.1 | 20.4 ± 10.4 | 0.591 | ||
PGA | 6.4 ± 1.2 | 3.4 ± 1.4 | 0.063 | ||
PhGA | 4.6 ± 0.9 | 2.5 ± 1.2 | 0.046 | ||
DAS28-CRP | 4.61 ± 0.51 | 2.96 ± 0.7 | 0.016 | ||
DAS28-ESR | 4.49 ± 0.72 | 3.15 ± 0.82 | 0.085 | ||
SDAI | 23.3 ± 5.53 | 10.8 ± 5.8 | 0.026 | ||
CDAI | 21.4 ± 5.1 | 9.9 ± 10.3 | 0.051 | ||
MTX dose | 11.4 ± 0.8 | ||||
BMI | 25.1 ± 1.8 | 24.7 ± 1.7 | 0.902 | ||
QRISK-2 score | 7.9 ± 10.2 | 18.9 ± 16.3 | 0.029 | ||
Hypertension | 4 (26.7%) | 5 (33.3%) | 0.5 | ||
Diabetes mellitus | 0 | 0 | 1.0 | ||
Hypercholesterolaemia | 4 (26.7%) | 7 (46.7%) | 0.449 | ||
Hypertrygliceridaemia | 2 (13.3%) | 3 (20.0%) | 0.5 |